Ronald Reagan UCLA Medical Center

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study

Retrieved on: 
Tuesday, November 7, 2023

SAN MATEO, Calif., Nov. 7, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion on its lead candidate Niyad™ (nafamostat) for use as an anticoagulant in dialysis circuits. The panel will feature two thought-leaders in the nephrology and critical care fields who are also co-authors on a recent market research manuscript reporting current issues with anticoagulants in the dialysis circuit. The panel will also discuss the NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) Study, a registrational study comparing Niyad with placebo for dialysis circuit anticoagulation, which is planned to start in the fourth quarter. Both panel members are principal investigators in the trial.

Key Points: 
  • The panel will feature two thought-leaders in the nephrology and critical care fields who are also co-authors on a recent market research manuscript reporting current issues with anticoagulants in the dialysis circuit.
  • The panel will also discuss the NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy) Study, a registrational study comparing Niyad with placebo for dialysis circuit anticoagulation, which is planned to start in the fourth quarter.
  • The webcasted event will take place on Wednesday, December 6, 2023 at 11:00 a.m.
  • A live question and answer will follow the discussion.

One of 2023's Must Read Children's Books Is the Heartwarming 'The Struggle Is Real' by Author Cynthia R. Essex-Carter

Retrieved on: 
Friday, October 27, 2023

San Francisco, California--(Newsfile Corp. - October 27, 2023) - Author Cynthia R. Essex-Carter has announced the release of a heartwarming new children's book, The Struggle Is Real: "It is Time to Make a Change" .

Key Points: 
  • San Francisco, California--(Newsfile Corp. - October 27, 2023) - Author Cynthia R. Essex-Carter has announced the release of a heartwarming new children's book, The Struggle Is Real: "It is Time to Make a Change" .
  • This uplifting story examines themes of jealousy and envy to teach young readers about the importance of self-love and the power of words.
  • The Struggle Is Real: "It is Time to Make a Change" is available for purchase on Amazon.com , Barnes & Noble , or wherever books are sold.
  • Cynthia R. Essex-Carter is a children's author from the small town of Grady, Arkansas.

The Inner Circle Acknowledges, Mark Plunkett as a Distinguished Medical Professional for his contributions to the field of Pediatric Cardiac Surgery

Retrieved on: 
Monday, October 30, 2023

PEORIA, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Mark Plunkett is acknowledged as a Distinguished Medical Professional for his contributions to the field of Pediatric Cardiac Surgery.

Key Points: 
  • PEORIA, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Mark Plunkett is acknowledged as a Distinguished Medical Professional for his contributions to the field of Pediatric Cardiac Surgery.
  • Dr. Plunkett began his higher education journey at Duke University where he earned a Bachelor of Science degree in Biology.
  • He then attended the University of North Carolina and earned a Medical Doctor degree; completed a residency in general and cardiothoracic surgery at Duke University, a nine-year program; and a fellowship in pediatric and congenital heart surgery at UCLA Medical Center/ Mattel Children's Hospital.
  • Board certified by the ABTS in cardiothoracic surgery and congenital heart surgery, Dr. Plunkett specializes in treating fetuses; infants; children; and adolescents with cardiovascular or cardiac abnormalities.

Nectar Life Sciences, the Health Technology Company Behind the First Hybrid, Vertically-Integrated Allergy Care Platform, Opens First Nectar Allergy Center in New York City

Retrieved on: 
Monday, August 28, 2023

Nectar Life Sciences , the trusted health technology company behind the first hybrid, vertically-integrated allergy care platform, today announced the grand opening of its flagship Nectar Allergy Center , located in New York City.

Key Points: 
  • Nectar Life Sciences , the trusted health technology company behind the first hybrid, vertically-integrated allergy care platform, today announced the grand opening of its flagship Nectar Allergy Center , located in New York City.
  • Nectar’s care offerings are now expanding from environmental allergies to more complex allergic conditions, including asthma, food allergies, and eczema.
  • Dr. Akansha Ganju, M.D., has also joined the company as Medical Director of the Nectar Allergy Center.
  • Increasing accessibility to comprehensive allergy care is a core part of Nectar Life Sciences’s mission, so the Allergy Center is strategically located near many subway and bus stops.

Alcott Enterprises Acquires Award-Winning I.T. Service Provider Shadow Systems

Retrieved on: 
Thursday, June 29, 2023

Alcott Enterprises is pleased to announce its acquisition of Shadow Systems, a family-owned, award-winning, national I.T.

Key Points: 
  • Alcott Enterprises is pleased to announce its acquisition of Shadow Systems, a family-owned, award-winning, national I.T.
  • “We have been a longtime partner with Bill, his son Mathew, and his Shadow Systems team.
  • The Yount family and Shadows Systems teams are excited to continue to offer best-in-class customer service with the excellent leadership of Jordan Alcott and the strategic advisors of the Alcott Enterprises team,” says Mathew Yount.
  • Over the next few months, the Alcott Enterprises team will work with Shadows Systems to finalize the acquisition by August.

Renowned Los Angeles Urologist, Dr. Justin Houman, Introduces Groundbreaking Shockwave Therapy for Erectile Dysfunction Treatment

Retrieved on: 
Thursday, June 8, 2023

LOS ANGELES, June 8, 2023 /PRNewswire-PRWeb/ -- Dr. Justin Houman, a leading urologist based in Los Angeles, is thrilled to announce the integration of Shockwave Therapy for the treatment of Erectile Dysfunction (ED). With this cutting-edge treatment, Dr. Houman aims to provide patients with a highly effective, non-invasive solution to overcome the challenges of ED and regain their sexual confidence.

Key Points: 
  • Dr. Houman is now treating patients who are suffering from Erectile Dysfunction in Los Angeles with Shockwave Therapy which is a new Breakthrough Erectile Dysfunction Treatment that offers patients the opportunity to return to normal sexual function with their partner.
  • LOS ANGELES, June 8, 2023 /PRNewswire-PRWeb/ -- Dr. Justin Houman, a leading urologist based in Los Angeles , is thrilled to announce the integration of Shockwave Therapy for the treatment of Erectile Dysfunction (ED).
  • "I am thrilled to offer Shockwave Therapy as a safe and effective solution for men struggling with Erectile Dysfunction," said Dr. Houman.
  • Dr. Justin Houman's clinic is located at 8635 W 3rd St, Suite 1W in Los Angeles, CA.

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within The Pain and Rehabilitation Medical Group in Torrance, California

Retrieved on: 
Tuesday, May 16, 2023

ROSELAND, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery systems that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into The Pain and Rehabilitation Medical Group in Torrance, California.

Key Points: 
  • ROSELAND, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery systems that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into The Pain and Rehabilitation Medical Group in Torrance, California.
  • Dr. Proano initially conducted eight cases using the CompuFlo Epidural system, in which he reported 100% success.
  • The evaluation included Epidural Steroid Injection (ESI) procedures within the lumbar, thoracic and cervical thoracic junction of the spine.
  • Dr. Proano also completed an advanced specialty fellowship in Interventional and Multidisciplinary Pain Management at UCLA Medical Center.

Sensydia Achieves Study Target for Heart-Sound AI

Retrieved on: 
Monday, February 6, 2023

Non-invasive cardiac assessment company Sensydia announced today that it has completed its 225-subject development study at the University of Pittsburgh Medical Center (UPMC).

Key Points: 
  • Non-invasive cardiac assessment company Sensydia announced today that it has completed its 225-subject development study at the University of Pittsburgh Medical Center (UPMC).
  • "When we began this study at UPMC during the height of the COVID-19 pandemic, our original enrollment target for the study was 110 subjects, but we ended up doubling that after hearing positive feedback from the UPMC study staff," said Anthony Arnold, President and CEO of Sensydia.
  • Sensydia plans to use data from this 225-subject study to develop the CPS pulmonary pressure algorithms.
  • In 2018, Sensydia received FDA 510(k) clearance for non-invasive measurement of ejection fraction by CPS, and in 2022, Sensydia CPS was granted Breakthrough Device Designation by the FDA.

Los Angeles Vasectomy and Vasectomy Reversal Specialist Dr. Justin Houman is Recognized as a 2023 Top Patient Rated Los Angeles Urologist by Find Local Doctors

Retrieved on: 
Thursday, January 19, 2023

LOS ANGELES, Jan. 19, 2023 /PRNewswire-PRWeb/ -- Board-certified urologist, Dr. Justin Houman, is one of the top men's health specialists and leading urological surgeons in the Los Angeles area. His impressive ratings and reviews have earned him this distinguished award from Find Local Doctors. Find Local Doctors is a user-friendly online directory, that helps consumers locate skilled physicians in their area. Dr. Justin Houman is passionate about making a difference in his patient's health with state-of-the-art technology and compassionate, personalized care. Dr. Houman's cutting-edge practice is centered on enhancing his patients' quality of life through comprehensive male urology to improve sexual function and achieve reproductive goals. He specializes in male fertility, erectile dysfunction, sexual performance, testosterone management and Peyronie's disease. Also, as a top minimally-invasive microscopic surgeon, Dr. Houman provides skill and expertise in microsurgical varicocelectomies, vasectomy reversals, sperm retrievals, penile implants and male incontinence. He offers exceptional male urological care, with a true commitment to patient satisfaction and successful results.

Key Points: 
  • LOS ANGELES, Jan. 19, 2023 /PRNewswire-PRWeb/ -- Board-certified urologist , Dr. Justin Houman, is one of the top men's health specialists and leading urological surgeons in the Los Angeles area.
  • His impressive ratings and reviews have earned him this distinguished award from Find Local Doctors.
  • Find Local Doctors is a user-friendly online directory, that helps consumers locate skilled physicians in their area.
  • Dr. Justin Houman is passionate about making a difference in his patient's health with state-of-the-art technology and compassionate, personalized care.

Cardiac Dimensions Raises $35 Million in Series D Financing

Retrieved on: 
Thursday, January 5, 2023

Cardiac Dimensions ®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced it has closed a $35 million Series D financing round.

Key Points: 
  • Cardiac Dimensions ®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced it has closed a $35 million Series D financing round.
  • Funds will also support expanded sales of the Carillon device in several European countries where it has full reimbursement.
  • This funding will enable us to continue providing Carillon therapy to a large population of patients in dire need of treatment,” said Cardiac Dimensions CEO Rick Wypych.
  • Previously published survival data on the Carillon device out to six years show favorable survival when compared to medical management.